Cornell’s Research
Serves the Region and Beyond

AffyImmune Therapeutics, Inc. CTL

R&D: Biopharmaceuticals

  • Products:
  • Chimeric Antigen Receptor T cells

AffyImmune Therapeutics is a biopharmaceutical company developing genetically engineered immune cells to fight cancer with the goal of realizing the revolutionary potential of cancer immunotherapy. The company's lead compound is designed to treat patients with advanced thyroid and other cancers that do not respond to other agents. AffyImmune's 5-year plan is to develop a pipeline of agents for treating a variety of solid cancers. These agents will show the utility of their technology platform.

Cornell Connection

AffyImmune Therapeutics' technology is based on work by a Cornell professor who is also a cofounder. The company has licensed the technology and is continuing development at Cornell.